Bli medlem
Bli medlem

Du är här


Swedish Orphan Biovitrum AB: European study of real-life haemophilia treatment emphasizes need to improve standard of care

Swedish Orphan Biovitrum AB (publ) ( (Sobi™)
(STO: SOBI) announces the results from a new European study that
assessed the efficacy of haemophilia care in real life. The study,
which was fully funded by Sobi, showed that treatment practice varied
widely between countries and that patients treated on-demand and
prophylactically both experienced bleeds, emphasizing the need for
further enhancing standard of care.

The authors concluded that prophylaxis should be considered for people
with frequent bleeds to avoid pain and deterioration of joint
function, and the treatment regimen for people on prophylaxis needs

The study has been published in the on-line issue of Haemophilia, the
official journal of the World Federation of Hemophilia[i]

"The overall results indicate that there is a significant need to
advance standard of care within haemophilia", said Stefan Lethagen,
Vice President Medical & Clinical Sciences, Haemophilia at Sobi.
"Even when prophylaxis is the norm, it appears that prophylactic
treatment is driven to the minimal acceptable level or even lower,
which increases the risk of joint injury and limits the ability to
live a full and active life."

The retrospective study included 1346 people with haemophilia A and
312 people with haemophilia B, from seven European countries. The
study was designed to provide insights into current haemophilia
treatment practice and outcome.

Prophylaxis was overall found to be the most dominating treatment for
people with severe haemophilia A. It was the most common treatment
regimen among children and decreased with increasing age. On-demand
treatment was reported to be most common in moderate haemophilia A,
and there was no trend across age groups. For people with haemophilia
B, prophylaxis was most common in four out of seven countries.

In this European study, the median ABR for patients with severe
haemophilia A on prophylaxis was as high as four in some countries
and some patients experienced more than 12 bleeds per year, likely
reflecting insufficient therapy, inappropriate dose-interval,
presence of target joints, poor adherence or difficulty of correctly
assessing bleeds by some patients. The authors emphasised that there
is also a need for improvement in individuals with moderate
haemophilia A on prophylaxis, since bleeds were as frequent or more
frequent than for those with severe disease on prophylaxis. The
overall results of the study indicate that there is room for
improvement of haemophilia therapy, even for patients currently on
prophylactic treatment.

- - -

About Haemophilia A and B
Haemophilia is a rare, genetic disorder in which the ability of a
person's blood to clot is impaired. Haemophilia A occurs in about one
in 5,000 male births annually, and more rarely in females.
Haemophilia B occurs in about one in 25,000 male births annually, and
more rarely in females. Worldwide, it is estimated that more than
400,000 people are living with haemophilia.

People with haemophilia A or B experience prolonged bleeding episodes
that can cause pain, irreversible joint damage and life-threatening
haemorrhages. Prophylactic infusions of factor VIII or IX can
temporarily replace the missing clotting factors that are needed to
control bleeding and prevent new bleeding episodes.[i]
The World Federation of Hemophilia recommends prophylaxis as the
optimal therapy as it can prevent bleedings and joint

About Sobi™
Sobi is an international specialty healthcare company dedicated to rare diseases. Sobi's mission is to develop and deliver innovative therapies and services to improve the lives of patients. The product portfolio is primarily focused on Haemophilia, Inflammation and Genetic diseases. Sobi also markets a portfolio of specialty and rare disease products across Europe, the Middle East, North Africa and Russia for partner companies. Sobi is a pioneer in biotechnology with world-class capabilities in protein biochemistry and biologics manufacturing. In 2015, Sobi had total revenues of SEK 3.2 billion (USD 385 M) and about 700 employees. The share (STO: SOBI) is listed on Nasdaq Stockholm. More information is available at

For more information please contact

Media relations Investor relations
Linda Holmström, Senior Jörgen Winroth, Vice
Communications Manager President, Head of Investor
T: + 46 708 73 40 95, + T: +1 347-224-0819, +1 212
46 8 697 31 74 -579-0506, +46 8 697 2135


To access original article go to:

Federation of Hemophilia. About Bleeding Disorders - Frequently Asked
Questions. Available at: Accessed on:
June 17, 2016.

Guideline for the management of hemophilia, World Federation of
Hemophilia, 2nd edition, Accessed on
December 2015

Swedish Orphan Biovitrum AB
Postal address SE-112 76 Stockholm, Sweden
Phone: +46 8 697 20 00


Författare WKR

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.